Consistent with our in vitro results, the SKOV3-bearing mouse group with high-dose SS administration showed GPx4 deficiency and reduced tumor growth compared with the vehicle-treated ovarian cancer mouse groups. This evidence concerns the gene GPX4 and ovarian carcinoma.